SCOPUS BIOPHARMA INC (SCPS) Stock Price, Quote, News and Overview
NASDAQ:SCPS - Nasdaq - US8091711015 - Common Stock - Currency: USD
SCPS Quote, Performance and Key Statistics
0.1682
-0.17 (-50.54%)
The current stock price of SCPS is 0.1682 USD. In the past month the price decreased by -30.61%. In the past year, price decreased by -91.55%.
SCPS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SCPS
Company Profile
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.
Company Info
SCOPUS BIOPHARMA INC
420 Lexington Ave Rm 300
New York City NEW YORK US
Employees: 9
Company Website: https://scopusbiopharma.com/
Phone: 12124792513.0
SCOPUS BIOPHARMA INC / SCPS FAQ
What is the stock price of SCOPUS BIOPHARMA INC today?
The current stock price of SCPS is 0.1682 USD. The price decreased by -50.54% in the last trading session.
What is the ticker symbol for SCOPUS BIOPHARMA INC stock?
The exchange symbol of SCOPUS BIOPHARMA INC is SCPS and it is listed on the Nasdaq exchange.
On which exchange is SCPS stock listed?
SCPS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCOPUS BIOPHARMA INC stock?
7 analysts have analysed SCPS and the average price target is 12.24 USD. This implies a price increase of 7177.05% is expected in the next year compared to the current price of 0.1682. Check the SCOPUS BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCOPUS BIOPHARMA INC worth?
SCOPUS BIOPHARMA INC (SCPS) has a market capitalization of 3.55M USD. This makes SCPS a Nano Cap stock.
How many employees does SCOPUS BIOPHARMA INC have?
SCOPUS BIOPHARMA INC (SCPS) currently has 9 employees.
Should I buy SCOPUS BIOPHARMA INC (SCPS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCPS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCPS, evaluating the profitability, health, valuation and growth aspects
- SCOPUS BIOPHARMA INC (SCPS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCOPUS BIOPHARMA INC (SCPS) Sales and EPS estimates to see what analysts future expectations are.
- SCOPUS BIOPHARMA INC (SCPS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCOPUS BIOPHARMA INC (SCPS) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCOPUS BIOPHARMA INC (SCPS) Stock Chart to make your own analysis
- SCOPUS BIOPHARMA INC (SCPS) Latest news and press-releases to stay up to date.
Does SCOPUS BIOPHARMA INC (SCPS) stock pay dividends?
SCPS does not pay a dividend.
What is the Price/Earnings (PE) ratio of SCOPUS BIOPHARMA INC (SCPS)?
SCOPUS BIOPHARMA INC (SCPS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
What is the Short Interest ratio of SCOPUS BIOPHARMA INC (SCPS) stock?
The outstanding short interest for SCOPUS BIOPHARMA INC (SCPS) is 0.15% of its float. Check the ownership tab for more information on the SCPS short interest.
SCPS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCPS. When comparing the yearly performance of all stocks, SCPS is a bad performer in the overall market: 93.7% of all stocks are doing better.
SCPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCPS. Both the profitability and financial health of SCPS have multiple concerns.
SCPS Financial Highlights
Over the last trailing twelve months SCPS reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 40.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCPS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SCPS. The Buy consensus is the average rating of analysts ratings from 7 analysts.